HC Wainwright Reaffirms “Neutral” Rating for Shattuck Labs (NASDAQ:STTK)

Shattuck Labs (NASDAQ:STTK)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports.

Other research analysts have also issued reports about the company. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Leerink Partners began coverage on shares of Shattuck Labs in a research note on Monday, March 17th. They set an “outperform” rating and a $4.00 target price for the company. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Stock Performance

NASDAQ:STTK opened at $1.06 on Thursday. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76. The company has a market cap of $50.37 million, a P/E ratio of -0.69 and a beta of 1.66. The stock’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.49.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. As a group, equities analysts predict that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Prosight Management LP increased its holdings in Shattuck Labs by 15.1% in the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after purchasing an additional 873,409 shares in the last quarter. Millennium Management LLC grew its holdings in Shattuck Labs by 37.0% during the 4th quarter. Millennium Management LLC now owns 201,214 shares of the company’s stock worth $243,000 after acquiring an additional 54,322 shares during the last quarter. Deutsche Bank AG increased its position in Shattuck Labs by 476.4% in the 4th quarter. Deutsche Bank AG now owns 116,868 shares of the company’s stock valued at $141,000 after acquiring an additional 96,594 shares during the period. Bank of America Corp DE raised its stake in shares of Shattuck Labs by 135.0% during the fourth quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock valued at $226,000 after acquiring an additional 107,491 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new position in shares of Shattuck Labs during the fourth quarter worth $1,270,000. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.